相关实验视频

Updated: Jan 16, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

通过癌症抗药性非编码RNA对cuproptosis的表观遗传修饰

Fei Du¹, Lu Tang², Fang Wang^3,4

¹Department of Pharmacy, The Fourth Affiliated Hospital Of Southwest Medical University, 620000, Meishan, Sichuan, PR China.

Molecular cancer

|September 26, 2025

概括

编程细胞死亡途径 - - 质亡 (Cuproptosis) 通过向线粒体,显示出对瘤耐药性的有前途. 非编码RNAs (ncRNAs) 从表观遗传学上调节cuproptosis,为克服治疗失败提供新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
细胞死亡研究细胞死亡研究

背景情况:

瘤耐药性是癌症治疗的一个主要障碍,导致治疗失败和复发.
细胞亡是一种编程细胞死亡的新型形式,准线粒体代谢,并提出了对抗药物耐药性的潜在策略.
针对线粒体的疗法面临挑战,因为它在正常组织中起着至关重要的作用,需要精确的调节机制.

研究的目的:

审查cuproptosis的机制及其在克服癌症耐药性的作用.
探索非编码RNAs (ncRNAs) 通过cuproptosis的表观遗传调节.
突出ncRNA-cuproptosis相互作用网络在治疗反应和癌症进展中的重要性.

主要方法:

文献综述总结了关于cuproptosis,耐药性和ncRNAs的当前研究.
对关联cuproptosis,表观遗传修饰和治疗结果的分子机制的分析.
综合关于在各种癌症治疗中通过ncRNA调节cuproptosis的发现.

主要成果:

型亡提供了一种新的方法,通过向癌细胞代谢来打击耐药性.
由ncRNAs介导的表观遗传变化可以动态地影响对cuproptosis的易感性.
ncRNAs在调节化学疗法,免疫疗法和通过cuproptosis向治疗的耐药性方面发挥着至关重要的作用.

结论:

该ncRNA-cuproptosis轴是瘤药物耐药性的关键调节器.
向ncRNAs和cuproptosis是一个有希望的治疗途径,可以克服治疗耐药性.
了解cuproptosis的ncRNA-表观遗传调制对于开发有效的癌症治疗非常重要.

关键词:

癌症癌症癌症癌症这种疾病叫做cuproptosis.药物耐药性药物耐药性药物耐药性表观遗传修饰是一种表观遗传修饰.没有编码的RNAs.

更多相关视频

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Epigenetic Regulation

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...

Epigenetic Regulation

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...